

# Cascade Polyketide and Polyene Cyclizations: Biomimetic Total Synthesis of Hongoquercin B

Tim N. Barrett and Anthony G. M. Barrett\*

Department of Chemistry, Imperial College London, London SW7 2AZ, England

**Supporting Information** 

**ABSTRACT:** The total synthesis of hongoquercin B was carried out in 9 steps from *trans,trans*-farnesyl acetate using a palladium catalyzed decarboxylative  $\pi$ -farnesyl rearrangement of a diketo-dioxinone ester, aromatization and cationic diene-epoxide cyclization as key steps. This cascade tetracyclization simplifies the synthesis of terpenoid resorcylate natural products.

T he hongoquercins (1), which were isolated from extracts of an unidentified terrestrial fungus, exhibit antibiotic activity against vancomycin-resistant *Enterococcus faecium* and methicillin-resistant *Staphylococcus aureus.*<sup>1</sup> They belong to a group of natural products known as the meroterpenoids– hybrid natural products composed of both terpenoid and polyketide-derived substructures.<sup>2,3</sup> Meroterpenoids containing the drimane-phenol ring system (such as 1) are known to exhibit antifungal, antiviral, and antitumor activities (Figure 1).<sup>4</sup>

Several total syntheses of these meroterpenoids and the hongoquercins have been reported,<sup>5,6</sup> and many have relied upon the coupling of a protected aromatic unit (7) with a cyclic terpenoid entity (6) derived from commercially available cyclic enantiopure natural products (Scheme 1). Herein we report a



Figure 1. Meroterpenoids containing drimane-phenol ring system.

Scheme 1. Synthetic Strategies to Hongoquercins (1)



Proposed Dual Biomimetic Route.



new biomimetic strategy for the synthesis of hongoquercin B, which utilizes total biomimetic cyclization reactions to construct both the resorcylate and tricyclic terpenoid substructures from an acylic precursor.

Recently, we have developed a flexible biomimetic strategy for the synthesis of several polyketide resorcylate natural products using late-stage aromatization from diketo-dioxinone precursors.<sup>7,8</sup> Inspired by the work of Stork, Eschenmoser and Johnson on terpenoid polyene cyclization reactions,<sup>9-11</sup> we considered that hongoquercin B (1b) should be available via a dual biomimetic approach where polyketide cyclo-aromatization is directly followed by a stereocontrolled diene epoxide cyclization to generate the tetracyclic core of the natural product (Scheme 1). The retrosynthetic analysis is outlined in Scheme 2 in which the drimane-phenol ring system should be available via a cationic epoxy-ene tricyclization terminated by the phenol nucleophile of terpene resorcylate 9. Smith and coworkers showed that a similar epoxy-ene cascade preferentially gave rise to the desired chair-chair tetracycle rather than the chair-boat isomer.<sup>12</sup> This cascade with dioxinone chemistry should allow for the control of 5 stereocenters in the natural product from a single stereocenter installed in the first step.

Resorcylate 9 should be available through base-mediated cyclo-aromatization of diketo-dioxinone 10 available from regioselective palladium(0)-catalyzed decarboxylative farnesyl

Received: November 10, 2014 Published: November 25, 2014



migration of dioxinone diketo ester **11** as developed within our group for other systems.<sup>7,13</sup> Diketo-dioxinone ester **11** should be available through double C-acylation of keto-dioxinone **12** with an activated carbonate ester derived from the known 10,11-(S)-epoxyfarnesol (**13**) and acetyl chloride.

10,11-(S)-Epoxyfarnesol (13) was prepared from *trans,trans*farnesyl acetate (14) via enantioselective Sharpless dihydroxylation and epoxide formation.<sup>14</sup> Reaction of alcohol 13 with excess of carbonyl diimidazole (CDI) at 0 °C gave the imidazolecarboxylate 15 which was directly allowed to react with the zinc dienolate from keto-dioxinone 12 to give ketoester 16 (Scheme 3) in a 70% yield over two steps from 13.





Communication

Magnesium chloride and pyridine mediated regioselective acetylation of keto-ester 10 gave the key intermediate diketoester 11. Treatment of ester 11 with  $Pd(PPh_3)_4$  at room temperature gave diketo-dioxinone 10, which was readily aromatized over silica gel to give the resorcylate 9 (Scheme 4) in 66% yield over 3 steps. It is important to note that only the desired linear *E*,*E*-isomer was observed in this sequence.





With the open chain epoxy-terpenoid resorcylate 9 in hand, studies on the use of both Lewis and Brønsted acids to induce the desired cascade cyclization were examined (Scheme 5).

## Scheme 5. Cationic Epoxy-diene Cascade



Gratifyingly reaction of epoxide 9 with boron trifluoride etherate in dichloromethane gave the tetracyclic resorcylate 8 (60%), which was isolated as a single diastereoisomer. The stereochemistry of the product was confirmed from subsequent transformations.

Transesterification of resorcylate 8 with ethanol and potassium carbonate gave hongoquercin B as its known ethyl

ester 20. At this stage the stereochemistry of ester 20 was confirmed by comparison of the <sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS and  $[\alpha]_D$  with data reported together and NOE correlations in the <sup>1</sup>H NMR spectrum between various hydrogens of ester 20.<sup>5b</sup>

In summary, the total synthesis of hongoquercin B (1b) has been completed in 9 steps from *trans,trans*-farnesyl acetate (14) using a double biomimetic strategy, a palladium(0) catalyzed regioselective decarboxylative farnesyl migration, cycloaromatization to produce the resorcylate and cationic epoxy-diene cyclization. The single epoxy-farnesyl stereocenter was used to control all the remaining 4 stereocenters of the tetracyclic core. Further applications of this dual biomimetic strategy for the syntheses of other bioactive meroterpenoids will be reported in due course.

## ASSOCIATED CONTENT

#### **S** Supporting Information

Complete experimental procedures, characterization of new compounds and comparison of <sup>1</sup>H NMR, <sup>13</sup>C NMR, IR, HRMS and  $[\alpha]_D$  of hongoquercin B ethyl ester 20 with published data. This material is available free of charge via the Internet at http://pubs.acs.org.

#### AUTHOR INFORMATION

#### **Corresponding Author**

agm.barrett@imperial.ac.uk

#### Notes

The authors declare no competing financial interest.

### ACKNOWLEDGMENTS

We thank GlaxoSmithKline for a generous endowment to A.G.M.B and the European Research Council for an Advanced Grant (267281).

# REFERENCES

(1) Roll, D. M.; Manning, J. K.; Carter, G. T. J. Antibiot. 1998, 51, 635.

(2) Geris, R.; Simpson, T. J. Nat. Prod. Rep. 2009, 26, 1063.

(3) Shiomi, K.; Tomoda, H. Pure Appl. Chem. 1999, 71, 1059.

(4) (a) Du, L.; Zhou, Y.-D.; Nagle, D. G. J. Nat. Prod. 2013, 76, 1175. (b) Ishibashi, F.; Sato, S.; Sakai, K.; Hirao, S.; Kuwano, K. Biosci. Biotechnol. Biochem. 2013, 77, 1120. (c) Kohmoto, S.; McConnell, O. J.; Wright, A.; Koehn, F.; Thompson, W.; Lui, M.; Snader, K. M. J. Nat. Prod. 1987, 50, 336. (d) Barrero, A. F.; Alvarez-Manzaneda, E. J.; Herrador, M. M.; Chahboun, R.; Galera, P. Bioorg. Med. Chem. Lett. 1999, 9, 2325. Gochfield, D. J.; El Sayed, K. A.; Yousaf, M.; Hu, J. F.; Bartyzel, P.; Dunbar, D. C.; Wilkins, S. P.; Zjawiony, J. K.; Schinazi, R. F.; Schlueter Wirtz, S. Mini Rev. Med. Chem. 2003, 3, 401. (e) El Sayed, K. A.; Bartyzel, P.; Shen, X.; Perry, T. L.; Zjawiony, J. K.; Hamann, M. T. Tetrahedron 2000, 56, 949. (f) Robinson, S. J.; Hoobler, E. K.; Riener, M.; Loveridge, S. T.; Tenney, K.; Valeriote, F. A.; Holman, T. R.; Crews, P. J. Nat. Prod. 2009, 72, 1857. (g) Gordaliza, M. Mar. Drugs 2010, 8, 2849. (h) Mogi, T.; Kawakami, T.; Arai, H.; Igarashi, Y.; Matsushita, K.; Mori, M.; Shiomi, K.; Omura, S.; Harada, S.; Kita, K. J. Biochem. 2009, 146, 383.

(5) For the syntheses of the hongoquercins: (a) Tsujimori, H.; Bando, M.; Mori, K. *Eur. J. Org. Chem.* **2000**, *2*, 297. (b) Tsujimori, H.; Mori, K. *Biosci. Biotechnol. Biochem.* **2000**, *64*, 1410. (c) Kurdyumov, A. V.; Hsung, R. P. *J. Am. Chem. Soc.* **2006**, *128*, 6272. (c) Rosen, B. R.; Simke, L. R.; Thuy-Boun, P. S.; Dixon, D. D.; Yu, J.-Q.; Baran, P. S. Angew. Chem., Int. Ed. **2013**, *52*, 7317.

(6) For examples of syntheses of other similar meroterpenoids: (a) Ishibashi, H.; Ishihara, K.; Yamamoto, H. J. Am. Chem. Soc. 2004, 126, 11122. (b) Trost, B. M.; Shen, H. C.; Surivet, J. Angew. Chem., Int. *Ed.* 2003, 42, 3943. (c) Trost, B. M.; Shen, H. C.; Surivet, J. J. Am. Chem. Soc. 2004, 126, 12565. (d) Trost, B. M.; Fleitz, F. J.; Watkins, W. J. J. Am. Chem. Soc. 1996, 118, 5146. (e) Liu, H.-J.; Ramani, B. Tetrahedron Lett. 1988, 29, 6721. (f) Kato, M.; Matsumura, Y.; Heima, K.; Fukamiya, N.; Kabuto, C.; Yoshikoshi, A. Tetrahedron 1987, 43, 711.

(7) Navarro, I.; Basset, J.-F.; Hebbe, S.; Major, S. M.; Werner, T.; Howsham, C.; Bräckow, J.; Barrett, A. G. M. *J. Am. Chem. Soc.* **2008**, *130*, 10293.

(8) Cordes, J.; Calo, F.; Anderson, K.; Pfaffeneder, T.; Laclef, S.; White, A. J. P.; Barrett, A. G. M. J. Org. Chem. 2012, 77, 652.

(9) Stork, G.; Burgstahler, A. W. J. Am. Chem. Soc. 1955, 77, 5068.
(10) Stadler, P. A.; Eschenmoser, A.; Schinz, H.; Stork, G. Helv. Chim. Acta 1957, 40, 2191.

(11) Johnson, W. S.; Wiedhaup, K.; Brady, S. F.; Olson, G. L. J. Am. Chem. Soc. 1968, 90, 5277.

(12) Smith, A. B.; Kinsho, T.; Sunazuka, T.; Omura, S. Tetrahedron Lett. **1996**, 37, 6461.

(13) Anderson, K.; Laclef, S.; Barrett, A. G. M. *Tetrahedron* **2014**, *70*, 5569.

(14) (a) Corey, E. J.; Noe, M. C.; Lin, S. *Tetrahedron Lett.* **1995**, *36*, 8741. (b) Domingo, V.; Silva, L.; Diéguez, H. R.; Arteaga, J. F.; Quílez del Moral, J. F.; Barrero, A. F. J. Org. Chem. **2009**, *74*, 6151.